Diatech files IND for infection agent

Article

Peptide-based imaging agent developer Diatech of Londonderry, NH, has filed an investigationalnew drug (IND) application with the Food and Drug Administrationfor a new radiopharmaceutical that detects infections of unknownorigin. The agent, Tc-99m P483H,

Peptide-based imaging agent developer Diatech of Londonderry, NH, has filed an investigationalnew drug (IND) application with the Food and Drug Administrationfor a new radiopharmaceutical that detects infections of unknownorigin. The agent, Tc-99m P483H, is a technetium-99m-labeled syntheticpeptide designed to home in on infection sites where white bloodcells are elevated as the body fights infection.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
New Research Examines Radiation Risks with CT Exposure Prior to Pregnancy
Diagnostic Imaging’s Weekly Scan: August 31 — September 6
New Echocardiography Research Suggests Emerging Marker for Cardiomyopathy Detection in Patients with Duchenne Muscular Dystrophy
© 2025 MJH Life Sciences

All rights reserved.